

eTheRNA immunotherapies NV has developed mRNA formulation technologies tailored towards specific administration routes and optimized mRNA expression and biodistribution.



Overview

eTheRNA's proprietary LNP formulation technologies enable intravenous delivery of mRNA **enhanced thermostability** and **multiple routes of administration**.

- LNPs for systemic delivery (specifically designed for cancer vaccines)
- Formulations designed for intratumoural and intramuscular delivery (contains a novel proprietary ionisable lipid)
- Lead route for prophylactic vaccines, preferentially distributed to the spleen (and not the liver)
- Polyplexes for intranasal delivery of prophylactic vaccines

1st generation LNP

- Proprietary lipid combination
- Optimized for systemic delivery
- Biodistribution focused on spleen
- Designed for cancer vaccines
- Late preclinical stage

2nd generation LNP

- Novel ionizable lipid
- Optimized for intra-tumoural and intra-muscular delivery
- Intra-tumoural immunomodulation and tumour disruption
- Lead route for prophylactic vaccines
- Strong emerging in vivo data

Polyplexes

- Designed for local delivery
- Nasal delivery focus
- Parallel intramuscular development
- Designed for Prophylactic vaccines
- Lead optimisation stage

